Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study
Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...
Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...
China Regulators Chart Steady Path for ‘Huiminbao’ Medical Insurance Schemes
The China Banking and Insurance Regulatory Commission (CBIRC) and National Healthcare Security Administration (NHSA) have...
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Changchun High & New Technology Industries to Launch GenSci125 Phase I Trial in US
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading Chinese pharmaceutical company,...
Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...
Sino Biopharmaceutical Commences Phase III Trial for Semaglutide Biosimilar in China
Sino Biopharmaceutical Ltd (HKG: 1177), a leading Chinese pharmaceutical company, has announced the initiation of...
Ocumension Therapeutics Sells $56.66 Million Stake in EyePoint Pharmaceuticals
Ocumension Therapeutics (HKG: 1477), a specialist in the ophthalmology sector in China, has announced plans...
Yifan Pharmaceutical Wins Nod for Generic Diazoxide Oral Suspension in China
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a Chinese pharmaceutical company, has announced that it has...
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...
Wuhan EasyDiagnosis Biomedicine Partners with Ailex Technology Group for Global Glycated Hemoglobin Testing Market
Wuhan EasyDiagnosis Biomedicine Co., Ltd (SHE: 002932), a Chinese biomedicine company, has announced a strategic...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
Drug Farm’s DF-003 Earns FDA Rare Pediatric Disease Designation for ROSAH Syndrome
Sino-US biotech company Drug Farm has announced that it has received Rare Pediatric Disease Designation...
SciClone Pharmaceuticals Teams Up with SPH Health and Hi Dr to Launch Internet Hospital in China
SciClone Pharmaceuticals Inc., (HKG: 6600), a prominent player in China’s pharmaceutical industry, has joined forces...
Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution
Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based...
XtalPi Forms Strategic Partnership with ABB Robotics to Automate Lab Workstations in China
Sino-US AI drug development company XtalPi (QuantumPharm, HKG: 2228) has entered into a strategic partnership...
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...